Vivimed announces the Export of 1st shipment to Canada - Famotidine tablets 40mg and 20mg

Vivimed Labs Limited ("Vivimed" or the Company), a niche Specialty Chemicals and Pharmaceuticals company, announced today, the Export of 1st shipment to Canada - Famotidine tablets 40mg and 20mg is Histamine H2 Receptor Antagonists manufactured in its Vivimed Hyderabad site which is approved by health CANADA". It is used (1) for the relief of heartburn, indigestion, upset stomach, sour stomach due to excess stomach acid, hyperacidity and / or acid indigestion and (2) for the prevention of the symptoms of excess stomach acid brought on by consuming food and/or beverages which may cause symptoms.

Commenting on the development, Ramesh Krishnamurthy, CEO of Vivimed Labs Ltd said, "Successful launch of Famotidine is a demonstration of Vivimed's COMO capability to prestigious Canada market in collaboration with a highly respected strategic partner. This sets the stage for exciting new range of COMO products. In the next 6 months Vivimed shall continue to leverage end to end capabilities to expand its COMO foot print."

Shares of VIVIMED LABS LTD. was last trading in BSE at Rs.28.95 as compared to the previous close of Rs. 28.05. The total number of shares traded during the day was 98022 in over 600 trades.

The stock hit an intraday high of Rs. 29.3 and intraday low of 27. The net turnover during the day was Rs. 2787051.

Source : Equity Bulls

Keywords